News

UroToday1d
Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting
• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...
UroToday2d
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...
UroToday3d
When Should We Use 18F-FDG PET? "Presentation" - Andrei Iagaru
When Should We Use 18F-FDG PET? "Presentation" - Andrei Iagaru ...
UroToday3d
SECuRE Trial Update: First Patient Treated in the Phase II Cohort Expansion
The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the recent ...
UroToday3d
Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.
To present the long-term outcomes of men with Grade Group (GG) 1 prostate cancer (PCa), included in the Prostate Cancer Research International Active Surveillance (PRIAS) study, and to assess the ...
UroToday4d
The Benefit of Short-Term Androgen Deprivation Therapy with Radiotherapy for Intermediate-Risk Prostate Cancer - Beyond the Abstract
Historically, short-term androgen deprivation therapy (ST-ADT) has been considered a mainstay of treatment for intermediate-risk prostate cancer (IR-PCa) based upon early randomized controlled trials ...
UroToday4d
Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma.
Small cell bladder cancer (SCBC) is a rare histologic variant of bladder cancer with an aggressive disease course and poor outcomes. Given its uncommon nature, there is a paucity of high-quality data ...
UroToday4d
Awareness and prevalence of testicular cancer among German firefighters.
To investigate the awareness about their occupational elevated risk for testicular cancer, we conducted a cross-sectional study among German firefighters, as studies indicate that firefighters may be ...
UroToday4d
Stage IV Prostate Cancer Presenting With a Low Prostate-Specific Antigen Level: A Case Report.
Prostate cancer is one of the most common cancers diagnosed in men and is typically monitored through prostate-specific antigen (PSA) levels. Metastatic prostate cancer usually presents with elevated ...
UroToday4d
Secondary malignancies after treatment of testicular germ cell tumors: a systematic review & meta-analysis.
Testicular germ cell tumours (TGCTs) are the most common malignancy in men 15-35 years of age. Management options for men with TGCTs include surgery, radiation and/or chemotherapy. Given TGCTs' ...
UroToday4d
Long-term outcome of radiation therapy for locoregional recurrence of upper tract urothelial carcinoma after nephroureterectomy.
The objective was to evaluate the survival outcomes associated with radiation therapy (RT) in cases of postoperative locoregional recurrence of upper tract urothelial carcinoma (UTUC) following ...
UroToday4d
Current update on pharmacological strategies of penile cancer.
Penile cancer considered an orphan malignancy - due to its low incidence - makes research and clinical development challenging. The limited understanding of molecular biology and genetic landscape ...